We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...

JPMorgan raised the firm’s price target on BridgeBio (BBIO) to $50 from $44 and keeps an Overweight rating on the shares. The firm surveyed 30 ...

The FDA has approved BridgeBio Pharma's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market showdown with its larger rival Pfizer.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target increased by equities researchers at JPMorgan Chase & ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat protein ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) was the recipient of unusually large options trading on Monday. Traders acquired 8,235 call options on the stock. This is an increase of 88% ...

March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced ...

Redburn Atlantic initiated coverage of BridgeBio with a Buy rating and $50 price target Therapeutic options for patients with transthyretin ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.